Leslie B. Tyson

4.2k total citations · 1 hit paper
64 papers, 3.2k citations indexed

About

Leslie B. Tyson is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Leslie B. Tyson has authored 64 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Surgery, 23 papers in Pulmonary and Respiratory Medicine and 18 papers in Oncology. Recurrent topics in Leslie B. Tyson's work include Nausea and vomiting management (25 papers), Lung Cancer Treatments and Mutations (18 papers) and Chemotherapy-induced organ toxicity mitigation (11 papers). Leslie B. Tyson is often cited by papers focused on Nausea and vomiting management (25 papers), Lung Cancer Treatments and Mutations (18 papers) and Chemotherapy-induced organ toxicity mitigation (11 papers). Leslie B. Tyson collaborates with scholars based in United States, United Kingdom and Venezuela. Leslie B. Tyson's co-authors include Mark G. Kris, Richard J. Gralla, Vincent A. Miller, Lee M. Krug, Susan Groshen, Barbara Pizzo, Naiyer A. Rizvi, Rebecca A. Clark, William Pao and Robert T. Heelan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Leslie B. Tyson

63 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →

Peers

Leslie B. Tyson

ONCOL

SURGE

PRM

PFM

Sigbjørn Smeland Norway

Harold O. Douglass United States

Jean Trédaniel France

Rudolf Maibach Switzerland

Shigemitsu Takashima Japan

Thomas Ruhstaller Switzerland

Marcia Cruz‐Correa United States

Gamini S. Soori United States

Masaru Narabayashi Japan

Shiying Yu China

Sigbjørn Smeland Norway

Leslie B. Tyson

858 ×0.6

ONCOL

509 ×0.4

SURGE

1.4k ×1.2

PRM

637 ×1.0

342 ×0.9

PFM

Citations per year, relative to Leslie B. Tyson Leslie B. Tyson (= 1×) peers Sigbjørn Smeland

Countries citing papers authored by Leslie B. Tyson

Since Specialization

Citations

This map shows the geographic impact of Leslie B. Tyson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leslie B. Tyson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leslie B. Tyson more than expected).

Fields of papers citing papers by Leslie B. Tyson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leslie B. Tyson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leslie B. Tyson. The network helps show where Leslie B. Tyson may publish in the future.

Co-authorship network of co-authors of Leslie B. Tyson

This figure shows the co-authorship network connecting the top 25 collaborators of Leslie B. Tyson. A scholar is included among the top collaborators of Leslie B. Tyson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leslie B. Tyson. Leslie B. Tyson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paik, Paul K., Charles M. Rudin, M. Catherine Pietanza, et al.. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 74(3). 481–485. 70 indexed citations

Azzoli, Christopher G., Jyoti D. Patel, Lee M. Krug, et al.. (2011). Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial. Journal of Thoracic Oncology. 6(11). 1915–1922. 10 indexed citations

Krug, Lee M., Tao Dao, Andrew Brown, et al.. (2010). WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunology Immunotherapy. 59(10). 1467–1479. 96 indexed citations

James, Leonard P., Christopher G. Azzoli, Lee M. Krug, et al.. (2007). Phase I study of the anitfolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 6. 1 indexed citations

Azzoli, Christopher G., Lee M. Krug, Vincent A. Miller, et al.. (2007). A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(7). 638–644. 11 indexed citations

Tyson, Leslie B.. (2007). Non-Small Cell Lung Cancer: New Hope for a Chronic Illness. Oncology nursing forum. 34(5). 963–970. 7 indexed citations

Krug, Lee M., John P. Crapanzano, Christopher G. Azzoli, et al.. (2005). Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein. Cancer. 103(10). 2128–2131. 117 indexed citations

Tyson, Leslie B., et al.. (2003). Nursing Assessment and Management of Dyspneic Patients With Lung Cancer. Clinical journal of oncology nursing. 7(3). 332–333. 7 indexed citations

Kris, Mark G., et al.. (1995). Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. Cancer. 76(5). 774–778. 5 indexed citations

10.

Baltzer, Lorraine, Mark G. Kris, Leslie B. Tyson, James R. Rigas, & Katherine M.W. Pisters. (1994). The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. Cancer. 73(3). 720–723. 5 indexed citations

11.

Tyson, Leslie B., Mark G. Kris, Lorraine Baltzer, et al.. (1994). Randomized Phase II Trial Comparing Two Versus Three Doses of Ondansetron When Used in Combination with Dexamethasone in Patients Receiving Cisplatin ≥100 mg/m2. American Journal of Clinical Oncology. 17(3). 269–272. 4 indexed citations

12.

Kris, Mark G., Rebecca A. Clark, Leslie B. Tyson, et al.. (1993). Phase II Trial of a Single Intravenous Dose of Ondansetron in Patients Receiving Cisplatin ≥ 100 mg/m2. American Journal of Clinical Oncology. 16(1). 77–80. 2 indexed citations

13.

Kris, Mark G. & Leslie B. Tyson. (1993). Tropisetron (ICS 205–930) : A selective 5-hydroxytryptamine antagonist. European Journal of Cancer. 29. S30–S32. 4 indexed citations

14.

Pisters, Katherine M.W., Mark G. Kris, Leslie B. Tyson, et al.. (1993). Midazolam in patients receiving anticancer chemotherapy and antiemetics. Journal of Pain and Symptom Management. 8(8). 519–524. 7 indexed citations

15.

Kris, Mark G., Lorraine Baltzer, Katherine M.W. Pisters, & Leslie B. Tyson. (1993). Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. Cancer. 72(S11). 3436–3442. 13 indexed citations

16.

Grant, Stefan C., Mark G. Kris, Richard J. Gralla, Rebecca A. Clark, & Leslie B. Tyson. (1993). Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy. Cancer Chemotherapy and Pharmacology. 31(6). 442–444. 3 indexed citations

17.

Kris, Mark G., et al.. (1989). Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.. Journal of Clinical Oncology. 7(1). 108–114. 180 indexed citations

18.

Kris, Mark G., Richard J. Gralla, Ross A. Clark, & Leslie B. Tyson. (1989). Phase II Trials of the Serotonin Antagonist GR38032F for the Control of Vomiting Caused by Cisplatin. JNCI Journal of the National Cancer Institute. 81(1). 42–46. 77 indexed citations

19.

Kris, Mark G., Richard J. Gralla, Rebecca A. Clark, & Leslie B. Tyson. (1988). Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.. Journal of Clinical Oncology. 6(4). 659–662. 106 indexed citations

20.

Kris, Mark G., Richard J. Gralla, Rebecca A. Clark, Leslie B. Tyson, & Susan Groshen. (1987). Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer. 60(11). 2816–2822. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact